21:43 , Jan 18, 2019 |  BioCentury  |  Product Development

ImmunoGen’s milestone year

Nearly three years after refocusing the company to boost long-term value creation, ImmunoGen Inc. expects 2019 to be the year the changes will begin to bear fruit, starting with Phase III data from its lead...
20:49 , Jan 18, 2019 |  BC Week In Review  |  Clinical News

Data presented at ASCO GI for Keytruda in esophageal cancers

Merck & Co. Inc. (NYSE:MRK) reported detailed data on Jan. 14 from the Phase III KEYNOTE-181 trial showing that Keytruda pembrolizumab monotherapy as second-line treatment for advanced or metastatic esophageal or esophagogastric junction carcinoma improved...
20:04 , Jan 18, 2019 |  BC Week In Review  |  Company News

Phoenix, Roche partner to develop TNBC biomarker

Phoenix Molecular Designs (Vancouver, B.C.) and Roche (SIX:ROG; OTCQX:RHHBY) partnered on Jan. 16 to develop a molecular diagnostic to help stratify triple-negative breast cancer patients. Roche will develop an assay to detect activation of RPS6KA3,...
13:43 , Jan 18, 2019 |  BC Extra  |  Clinical News

Lartruvo fails confirmatory study; Lilly suspending promotion

Eli Lilly and Co. (NYSE:LLY) said it will suspend promotion of Lartruvo olaratumab after it missed the primary endpoints of the Phase III ANNOUNCE study to treat advanced or metastatic soft tissue sarcoma. The trial...
17:34 , Jan 17, 2019 |  BC Week In Review  |  Clinical News

Aslan reports gastric, biliary tract cancer data for varlitinib

Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) said Jan. 14 that its pan-HER inhibitor varlitinib missed the primary endpoint of a Phase II trial to treat gastric cancer. The study evaluated varlitinib as a first-line therapy in...
00:53 , Jan 17, 2019 |  BC Extra  |  Company News

Phoenix, Roche partner to develop TNBC biomarker

Phoenix Molecular Designs (Vancouver, B.C.) and Roche (SIX:ROG; OTCQX:RHHBY) partnered on Wednesday to develop a molecular diagnostic to help stratify triple-negative breast cancer patients. Roche will develop an assay to detect activation of RPS6KA3, which...
22:52 , Jan 15, 2019 |  BC Week In Review  |  Company News

AZ's Bohen departing after cancer-focused tenure

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Sean Bohen is leaving as CMO and EVP of global medicines development after a tenure marked by mixed results for the pharma's checkpoint inhibitor. Shortly after Bohen joined the pharma...
23:49 , Jan 14, 2019 |  BC Extra  |  Company News

AZ's Bohen departing after cancer-focused tenure

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Sean Bohen is leaving as CMO and EVP of global medicines development after a tenure marked by mixed results for the pharma's checkpoint inhibitor. Shortly after Bohen joined the pharma...
15:08 , Jan 14, 2019 |  BC Extra  |  Clinical News

Aslan dips after Phase II gastric cancer miss

Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) said its pan-HER inhibitor varlitinib missed the primary endpoint of a Phase II trial to treat gastric cancer. Aslan shares slid $2.75 (10%) to $24.90 in Taipei on Monday, and...
18:10 , Jan 11, 2019 |  BC Week In Review  |  Clinical News

Opdivo meets OS endpoint in esophageal cancer trial

Ono Pharmaceutical Co. Ltd. (Tokyo:4528) said anti-PD-1 mAb Opdivo nivolumab met the primary endpoint vs. chemotherapy of improving overall survival in the Phase III ATTRACTION-3 trial to treat esophageal cancer. Ono said Opdivo is the...